Reprogramming the immune system using antibodies.

Reprogramming the immune system using antibodies.

Tolerance induction induced by monoclonal antibodies or co-receptor blockade is robust enough to resist breakdown by adoptive transfer of lymphocytes. Such resistance, the hallmark of dominant tolerance, is mediated by CD4+ regulatory T cells. CD4+CD25+ T cells inhibit lymphopenia-mediated accumulat...

Descrizione completa

Dettagli Bibliografici
Autori principali:	Graca, L, Waldmann, H
Natura:	Journal article
Lingua:	English
Pubblicazione:	2006

Documenti analoghi

Reprogramming the immune system for tolerance with monoclonal antibodies.
di: Cobbold, S, et al.
Pubblicazione: (1990)

Reprogramming the immune system.
di: Waldmann, H
Pubblicazione: (2008)

Reprogramming the immune system.
di: Waldmann, H
Pubblicazione: (2002)

REPROGRAMMING THE IMMUNE-SYSTEM
di: Waldmann, H, et al.
Pubblicazione: (1993)

Reprogramming the immune system for peripheral tolerance with CD4 and CD8 monoclonal antibodies.
di: Cobbold, S, et al.
Pubblicazione: (1992)

Prospects for reprogramming the immune system in multiple sclerosis
di: Waldmann, H
Pubblicazione: (2007)

Reprogramming the immune system towards regulation
di: Waldmann, H, et al.
Pubblicazione: (2010)

Reprogramming the immune system: co-receptor blockade as a paradigm for harnessing tolerance mechanisms.
di: Waldmann, H, et al.
Pubblicazione: (2008)

Reprogramming the immune system: a possible therapeutic approach to established autoimmune disease.
di: Waldmann, H, et al.
Pubblicazione: (1993)

INTERACTION OF MONOCLONAL-ANTIBODIES WITH THE IMMUNE-SYSTEM
di: Clark, M, et al.
Pubblicazione: (1986)

Antibody-induced transplantation tolerance: the role of dominant regulation.
di: Graca, L, et al.
Pubblicazione: (2003)

Similarities in the Metabolic Reprogramming of Immune System and Endothelium
di: Chu-Yik Tang, et al.
Pubblicazione: (2017-07-01)

GPC2 antibody–drug conjugate reprograms the neuroblastoma immune milieu to enhance macrophage-driven therapies
di: Paul M Sondel, et al.
Pubblicazione: (2022-12-01)

Human monoclonal antibodies: the residual challenge of antibody immunogenicity.
di: Waldmann, H
Pubblicazione: (2014)

Cutting edge: anti-CD154 therapeutic antibodies induce infectious transplantation tolerance.
di: Graca, L, et al.
Pubblicazione: (2000)

The use of monoclonal antibodies to achieve immunological tolerance.
di: Waldmann, H, et al.
Pubblicazione: (1993)

The use of monoclonal antibodies to achieve immunological tolerance.
di: Waldmann, H, et al.
Pubblicazione: (1993)

Immunotherapy of Cancer: Reprogramming Tumor-Immune Crosstalk
di: Kyle K. Payne, et al.
Pubblicazione: (2012-01-01)

Understanding and Modulating Immunity With Cell Reprogramming
di: Cristiana F. Pires, et al.
Pubblicazione: (2019-12-01)

The cancer metabolic reprogramming and immune response
di: Longzheng Xia, et al.
Pubblicazione: (2021-02-01)

MONOCLONAL-ANTIBODY THERAPY IN SYSTEMIC VASCULITIS
di: Mathieson, P, et al.
Pubblicazione: (1990)

Mitochondrial metabolic reprogramming of macrophages and T cells enhances CD47 antibody-engineered oncolytic virus antitumor immunity
di: Ping Cheng, et al.
Pubblicazione: (2024-12-01)

Control of immune-mediated disease of the central nervous system with monoclonal (CD4-specific) antibodies.
di: O'Neill, J, et al.
Pubblicazione: (1993)

Lipid Metabolism Reprogramming of Immune Cells in Acne: An Update
di: Wu S, et al.
Pubblicazione: (2023-09-01)

Reprogramming systemic and local immune function to empower immunotherapy against glioblastoma
di: Songlei Zhou, et al.
Pubblicazione: (2023-01-01)

Prospects for the application of antibodies in medicine.
di: Waldmann, H
Pubblicazione: (2000)

SIRPα antibody combined with oncolytic virus OH2 protects against tumours by activating innate immunity and reprogramming the tumour immune microenvironment
di: Defeng Kong, et al.
Pubblicazione: (2022-10-01)

Regulation of Immune Cell Functions by Metabolic Reprogramming
di: Jaehong Kim
Pubblicazione: (2018-01-01)

Targeting macrophages to reprogram the tumor immune microenvironment
di: Zhidong Xie, et al.
Pubblicazione: (2024-10-01)

Metabolic Reprogramming and Immune Evasion in Nasopharyngeal Carcinoma
di: Huimei Huang, et al.
Pubblicazione: (2021-09-01)

Polylactide Degradation Activates Immune Cells by Metabolic Reprogramming
di: Chima V. Maduka, et al.
Pubblicazione: (2023-11-01)

Impact of epigenetic reprogramming on antitumor immune responses in glioma
di: Brandon L. McClellan, et al.
Pubblicazione: (2023-01-01)

Manipulation of T-cell responses with monoclonal antibodies.
di: Waldmann, H
Pubblicazione: (1989)

The major histocompatibility system and the immune response.
di: Munro, A, et al.
Pubblicazione: (1978)

Hybrid antibodies for therapy.
di: Clark, M, et al.
Pubblicazione: (1988)

Limiting dilution analysis of the cells of immune system I. The clonal basis of the immune response.
di: Lefkovits, I, et al.
Pubblicazione: (1984)

THERAPY WITH HYBRID ANTIBODIES
di: Clark, M, et al.
Pubblicazione: (1989)

Monoclonal antibodies for organ transplantation: prospects for the future.
di: Waldmann, H
Pubblicazione: (1988)

TOLERANCE INDUCTION USING CD4 AND CD8 MONOCLONAL-ANTIBODIES
di: Waldmann, H, et al.
Pubblicazione: (1989)

Human placental exosomes induce maternal systemic immune tolerance by reprogramming circulating monocytes
di: Kunfeng Bai, et al.
Pubblicazione: (2022-02-01)